371 related articles for article (PubMed ID: 31682427)
1. Advances in Discovering Deubiquitinating Enzyme (DUB) Inhibitors.
Schauer NJ; Magin RS; Liu X; Doherty LM; Buhrlage SJ
J Med Chem; 2020 Mar; 63(6):2731-2750. PubMed ID: 31682427
[TBL] [Abstract][Full Text] [Related]
2. Small molecules as tools for functional assessment of deubiquitinating enzyme function.
Magin RS; Liu X; Felix A; Bratt AS; Chan WC; Buhrlage SJ
Cell Chem Biol; 2021 Jul; 28(7):1090-1100. PubMed ID: 34089649
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of selective deubiquitinase inhibitors.
Varca AC; Casalena D; Chan WC; Hu B; Magin RS; Roberts RM; Liu X; Zhu H; Seo HS; Dhe-Paganon S; Marto JA; Auld D; Buhrlage SJ
Cell Chem Biol; 2021 Dec; 28(12):1758-1771.e13. PubMed ID: 34129829
[TBL] [Abstract][Full Text] [Related]
4. Diarylcarbonates are a new class of deubiquitinating enzyme inhibitor.
Long MJC; Lawson AP; Baggio R; Qian Y; Rozhansky L; Fasci D; El Oualid F; Weerapana E; Hedstrom L
Bioorg Med Chem Lett; 2019 Jan; 29(2):204-211. PubMed ID: 30528168
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitinases: From mechanisms to their inhibition by small molecules.
Lange SM; Armstrong LA; Kulathu Y
Mol Cell; 2022 Jan; 82(1):15-29. PubMed ID: 34813758
[TBL] [Abstract][Full Text] [Related]
6. Chemical and semisynthetic approaches to study and target deubiquitinases.
Gopinath P; Ohayon S; Nawatha M; Brik A
Chem Soc Rev; 2016 Jul; 45(15):4171-98. PubMed ID: 27049734
[TBL] [Abstract][Full Text] [Related]
7. Cell-Permeable Activity-Based Ubiquitin Probes Enable Intracellular Profiling of Human Deubiquitinases.
Gui W; Ott CA; Yang K; Chung JS; Shen S; Zhuang Z
J Am Chem Soc; 2018 Oct; 140(39):12424-12433. PubMed ID: 30240200
[TBL] [Abstract][Full Text] [Related]
8. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of DUBs Regulation in Signaling and Disease.
Li Y; Reverter D
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498168
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of deubiquitylating enzymes in tumorigenesis and development.
Cheng J; Guo J; North BJ; Wang B; Cui CP; Li H; Tao K; Zhang L; Wei W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188312. PubMed ID: 31449841
[TBL] [Abstract][Full Text] [Related]
11. Targeting Deubiquitinating Enzymes in Glioblastoma Multiforme: Expectations and Challenges.
Jin WL; Mao XY; Qiu GZ
Med Res Rev; 2017 May; 37(3):627-661. PubMed ID: 27775833
[TBL] [Abstract][Full Text] [Related]
12. Targeting the signalling pathways regulated by deubiquitinases for prostate cancer therapeutics.
Islam MT; Zhou X; Chen F; Khan MA; Fu J; Chen H
Cell Biochem Funct; 2019 Jul; 37(5):304-319. PubMed ID: 31062387
[TBL] [Abstract][Full Text] [Related]
13. The role of deubiquitinating enzymes in cancer drug resistance.
Tanguturi P; Kim KS; Ramakrishna S
Cancer Chemother Pharmacol; 2020 Apr; 85(4):627-639. PubMed ID: 32146496
[TBL] [Abstract][Full Text] [Related]
14. Small molecule screening identifies inhibitors of the Epstein-Barr virus deubiquitinating enzyme, BPLF1.
Atkins SL; Motaib S; Wiser LC; Hopcraft SE; Hardy PB; Shackelford J; Foote P; Wade AH; Damania B; Pagano JS; Pearce KH; Whitehurst CB
Antiviral Res; 2020 Jan; 173():104649. PubMed ID: 31711927
[TBL] [Abstract][Full Text] [Related]
15. Deubiquitylating enzymes and drug discovery: emerging opportunities.
Harrigan JA; Jacq X; Martin NM; Jackson SP
Nat Rev Drug Discov; 2018 Jan; 17(1):57-78. PubMed ID: 28959952
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of deubiquitinases inhibitors as antitumor agents.
Zheng LL; Wang LT; Pang YW; Sun LP; Shi L
Eur J Med Chem; 2024 Feb; 266():116161. PubMed ID: 38262120
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting the deubiquitinating enzymes (DUBs).
Ndubaku C; Tsui V
J Med Chem; 2015 Feb; 58(4):1581-95. PubMed ID: 25364867
[TBL] [Abstract][Full Text] [Related]
18. Identification of deubiquitinase inhibitors via high-throughput screening using a fluorogenic ubiquitin-rhodamine assay.
Varca AC; Casalena D; Auld D; Buhrlage SJ
STAR Protoc; 2021 Dec; 2(4):100896. PubMed ID: 34723213
[TBL] [Abstract][Full Text] [Related]
19. Profiling the Activity of Deubiquitinating Enzymes Using Chemically Synthesized Ubiquitin-Based Probes.
Leestemaker Y; de Jong A; Ovaa H
Methods Mol Biol; 2017; 1491():113-130. PubMed ID: 27778285
[TBL] [Abstract][Full Text] [Related]
20. Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.
Chen X; Yang Q; Xiao L; Tang D; Dou QP; Liu J
Cancer Metastasis Rev; 2017 Dec; 36(4):655-668. PubMed ID: 29039082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
